Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

What Was Tested

The paper reports a study of Insulin Detemir and NPH Insulin (isophane), published as a randomized controlled trial.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Forty-eight type 2 diabetic patients belonging to different ethnic groups (three groups of 16 African Americans (AA), 16 Hispanics/Latinos (HL) and 16 Caucasians) participated in this double-blind crossover trial.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The patients were allocated by chance, so the Insulin Detemir group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Insulin Detemir.

Each person switched between Insulin Detemir and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Black or African American, Body Mass Index, Diabetes Mellitus, Type 2, Glucose Clamp Technique, Hispanic or Latino, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Detemir and NPH Insulin (isophane) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2006 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page.